Microcarrier culture system for human influenza vaccine
DESCRIPTION (Provided by Applicant): The goal of the research herein proposed
is to develop a microcarrier - bioreactor - cell culture-based protocol that
enables the rapid, efficient, low cost production of human influenza vaccine.
Currently, virtually all human influenza virus vaccine is produced in
embryonated eggs. The Federal government and the World Health Organization are
actively seeking alternative cell culture approaches to flu vaccine production
since there are several problems with the egg-derived vaccines. A cell
culture-based protocol, with its potential to rapidly achieve large scale,
would be invaluable in the case of an influenza pandemic. A new microcarrier
substrate (Hillex), developed by SoloHill (under grant CA74595) has been shown
to support attachment and growth of a variety of low adhesive cells in
sera-free media and shows promise for this application. To achieve this
research goal, the following two specific aims will be performed.
Specific Aim I. To demonstrate feasibility for growing two different cell types
(Vero and MDCK) on Hillex microcarriers and identify critical cell culture
variables that will provide high cell yields on this substrate under serum-free
Specific Aim II. To demonstrate influenza virus production on Vero and MDCK
cells maintained on Hillex microcarriers (others have demonstrated that either
Vero or MDCK cells can feasibly be used to propagate human influenza virus)
under optimized bioreactor-type conditions.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
Small Business Information at Submission:
Principal Investigator:William J. Hillegas
SOLOHILL ENGINEERING, INC.
4220 VARSITY DR ANN ARBOR, MI 48108
Number of Employees: